SARS-CoV-2 evolution during treatment of chronic infection
The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for virus infection through the engagement of the human ACE2 protein1 and is a major antibody target. Here we show that chronic infection with SARS-CoV-2 leads to viral evolution and reduced sensitivity to neutralizing antibodies in an immunosuppressed individual treated with convalescent plasma, by generating whole-genome ultra-deep sequences for 23 time points that span 101 days and using in vitro techniques to characterize the mutations revealed by sequencing. There was little change in the overall structure of the viral population after two courses of remdesivir during the first 57 days. However, after convalescent plasma therapy, we observed large, dynamic shifts in the viral population, with the emergence of a dominant viral strain that contained a substitution (D796H) in the S2 subunit and a deletion (ΔH69/ΔV70) in the S1 N-terminal domain of the spike protein. As passively transferred serum antibodies diminished, viruses with the escape genotype were reduced in frequency, before returning during a final, unsuccessful course of convalescent plasma treatment. In vitro, the spike double mutant bearing both ΔH69/ΔV70 and D796H conferred modestly decreased sensitivity to convalescent plasma, while maintaining infectivity levels that were similar to the wild-type virus.The spike substitution mutant D796H appeared to be the main contributor to the decreased susceptibility to neutralizing antibodies, but this mutation resulted in an infectivity defect. The spike deletion mutant ΔH69/ΔV70 had a twofold higher level of infectivity than wild-type SARS-CoV-2, possibly compensating for the reduced infectivity of the D796H mutation. These data reveal strong selection on SARS-CoV-2 during convalescent plasma therapy, which is associated with the emergence of viral variants that show evidence of reduced susceptibility to neutralizing antibodies in immunosuppressed individuals.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:592 |
|---|---|
| Enthalten in: |
Nature - 592(2021), 7853 vom: 03. Apr., Seite 277-282 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kemp, Steven A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.04.2021 Date Revised 14.02.2024 published: Print-Electronic UpdateOf: medRxiv. 2020 Dec 29;:. - PMID 33398302 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41586-021-03291-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321063031 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321063031 | ||
| 003 | DE-627 | ||
| 005 | 20240214232258.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41586-021-03291-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM321063031 | ||
| 035 | |a (NLM)33545711 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kemp, Steven A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 evolution during treatment of chronic infection |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.04.2021 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: medRxiv. 2020 Dec 29;:. - PMID 33398302 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for virus infection through the engagement of the human ACE2 protein1 and is a major antibody target. Here we show that chronic infection with SARS-CoV-2 leads to viral evolution and reduced sensitivity to neutralizing antibodies in an immunosuppressed individual treated with convalescent plasma, by generating whole-genome ultra-deep sequences for 23 time points that span 101 days and using in vitro techniques to characterize the mutations revealed by sequencing. There was little change in the overall structure of the viral population after two courses of remdesivir during the first 57 days. However, after convalescent plasma therapy, we observed large, dynamic shifts in the viral population, with the emergence of a dominant viral strain that contained a substitution (D796H) in the S2 subunit and a deletion (ΔH69/ΔV70) in the S1 N-terminal domain of the spike protein. As passively transferred serum antibodies diminished, viruses with the escape genotype were reduced in frequency, before returning during a final, unsuccessful course of convalescent plasma treatment. In vitro, the spike double mutant bearing both ΔH69/ΔV70 and D796H conferred modestly decreased sensitivity to convalescent plasma, while maintaining infectivity levels that were similar to the wild-type virus.The spike substitution mutant D796H appeared to be the main contributor to the decreased susceptibility to neutralizing antibodies, but this mutation resulted in an infectivity defect. The spike deletion mutant ΔH69/ΔV70 had a twofold higher level of infectivity than wild-type SARS-CoV-2, possibly compensating for the reduced infectivity of the D796H mutation. These data reveal strong selection on SARS-CoV-2 during convalescent plasma therapy, which is associated with the emergence of viral variants that show evidence of reduced susceptibility to neutralizing antibodies in immunosuppressed individuals | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Mutant Proteins |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a remdesivir |2 NLM | |
| 650 | 7 | |a 3QKI37EEHE |2 NLM | |
| 650 | 7 | |a Adenosine Monophosphate |2 NLM | |
| 650 | 7 | |a 415SHH325A |2 NLM | |
| 650 | 7 | |a Alanine |2 NLM | |
| 650 | 7 | |a OF5P57N2ZX |2 NLM | |
| 700 | 1 | |a Collier, Dami A |e verfasserin |4 aut | |
| 700 | 1 | |a Datir, Rawlings P |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreira, Isabella A T M |e verfasserin |4 aut | |
| 700 | 1 | |a Gayed, Salma |e verfasserin |4 aut | |
| 700 | 1 | |a Jahun, Aminu |e verfasserin |4 aut | |
| 700 | 1 | |a Hosmillo, Myra |e verfasserin |4 aut | |
| 700 | 1 | |a Rees-Spear, Chloe |e verfasserin |4 aut | |
| 700 | 1 | |a Mlcochova, Petra |e verfasserin |4 aut | |
| 700 | 1 | |a Lumb, Ines Ushiro |e verfasserin |4 aut | |
| 700 | 1 | |a Roberts, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Chandra, Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Temperton, Nigel |e verfasserin |4 aut | |
| 700 | 0 | |a CITIID-NIHR BioResource COVID-19 Collaboration |e verfasserin |4 aut | |
| 700 | 0 | |a COVID-19 Genomics UK (COG-UK) Consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Sharrocks, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Blane, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Modis, Yorgo |e verfasserin |4 aut | |
| 700 | 1 | |a Leigh, Kendra E |e verfasserin |4 aut | |
| 700 | 1 | |a Briggs, John A G |e verfasserin |4 aut | |
| 700 | 1 | |a van Gils, Marit J |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Kenneth G C |e verfasserin |4 aut | |
| 700 | 1 | |a Bradley, John R |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Doffinger, Rainer |e verfasserin |4 aut | |
| 700 | 1 | |a Ceron-Gutierrez, Lourdes |e verfasserin |4 aut | |
| 700 | 1 | |a Barcenas-Morales, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Pollock, David D |e verfasserin |4 aut | |
| 700 | 1 | |a Goldstein, Richard A |e verfasserin |4 aut | |
| 700 | 1 | |a Smielewska, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Skittrall, Jordan P |e verfasserin |4 aut | |
| 700 | 1 | |a Gouliouris, Theodore |e verfasserin |4 aut | |
| 700 | 1 | |a Goodfellow, Ian G |e verfasserin |4 aut | |
| 700 | 1 | |a Gkrania-Klotsas, Effrossyni |e verfasserin |4 aut | |
| 700 | 1 | |a Illingworth, Christopher J R |e verfasserin |4 aut | |
| 700 | 1 | |a McCoy, Laura E |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Ravindra K |e verfasserin |4 aut | |
| 700 | 1 | |a Baker, Stephen |e investigator |4 oth | |
| 700 | 1 | |a Dougan, Gordon |e investigator |4 oth | |
| 700 | 1 | |a Hess, Christoph |e investigator |4 oth | |
| 700 | 1 | |a Kingston, Nathalie |e investigator |4 oth | |
| 700 | 1 | |a Lehner, Paul J |e investigator |4 oth | |
| 700 | 1 | |a Lyons, Paul A |e investigator |4 oth | |
| 700 | 1 | |a Matheson, Nicholas J |e investigator |4 oth | |
| 700 | 1 | |a Owehand, Willem H |e investigator |4 oth | |
| 700 | 1 | |a Saunders, Caroline |e investigator |4 oth | |
| 700 | 1 | |a Summers, Charlotte |e investigator |4 oth | |
| 700 | 1 | |a Thaventhiran, James E D |e investigator |4 oth | |
| 700 | 1 | |a Toshner, Mark |e investigator |4 oth | |
| 700 | 1 | |a Weekes, Michael P |e investigator |4 oth | |
| 700 | 1 | |a Bucke, Ashlea |e investigator |4 oth | |
| 700 | 1 | |a Calder, Jo |e investigator |4 oth | |
| 700 | 1 | |a Canna, Laura |e investigator |4 oth | |
| 700 | 1 | |a Domingo, Jason |e investigator |4 oth | |
| 700 | 1 | |a Elmer, Anne |e investigator |4 oth | |
| 700 | 1 | |a Fuller, Stewart |e investigator |4 oth | |
| 700 | 1 | |a Harris, Julie |e investigator |4 oth | |
| 700 | 1 | |a Hewitt, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Kennet, Jane |e investigator |4 oth | |
| 700 | 1 | |a Jose, Sherly |e investigator |4 oth | |
| 700 | 1 | |a Kourampa, Jenny |e investigator |4 oth | |
| 700 | 1 | |a Meadows, Anne |e investigator |4 oth | |
| 700 | 1 | |a O'Brien, Criona |e investigator |4 oth | |
| 700 | 1 | |a Price, Jane |e investigator |4 oth | |
| 700 | 1 | |a Publico, Cherry |e investigator |4 oth | |
| 700 | 1 | |a Rastall, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Ribeiro, Carla |e investigator |4 oth | |
| 700 | 1 | |a Rowlands, Jane |e investigator |4 oth | |
| 700 | 1 | |a Ruffolo, Valentina |e investigator |4 oth | |
| 700 | 1 | |a Tordesillas, Hugo |e investigator |4 oth | |
| 700 | 1 | |a Bullman, Ben |e investigator |4 oth | |
| 700 | 1 | |a Dunmore, Benjamin J |e investigator |4 oth | |
| 700 | 1 | |a Fawke, Stuart |e investigator |4 oth | |
| 700 | 1 | |a Gräf, Stefan |e investigator |4 oth | |
| 700 | 1 | |a Hodgson, Josh |e investigator |4 oth | |
| 700 | 1 | |a Huang, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Hunter, Kelvin |e investigator |4 oth | |
| 700 | 1 | |a Jones, Emma |e investigator |4 oth | |
| 700 | 1 | |a Legchenko, Ekaterina |e investigator |4 oth | |
| 700 | 1 | |a Matara, Cecilia |e investigator |4 oth | |
| 700 | 1 | |a Martin, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Mescia, Federica |e investigator |4 oth | |
| 700 | 1 | |a O'Donnell, Ciara |e investigator |4 oth | |
| 700 | 1 | |a Pointon, Linda |e investigator |4 oth | |
| 700 | 1 | |a Pond, Nicole |e investigator |4 oth | |
| 700 | 1 | |a Shih, Joy |e investigator |4 oth | |
| 700 | 1 | |a Sutcliffe, Rachel |e investigator |4 oth | |
| 700 | 1 | |a Tilly, Tobias |e investigator |4 oth | |
| 700 | 1 | |a Treacy, Carmen |e investigator |4 oth | |
| 700 | 1 | |a Tong, Zhen |e investigator |4 oth | |
| 700 | 1 | |a Wood, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Wylot, Marta |e investigator |4 oth | |
| 700 | 1 | |a Bergamaschi, Laura |e investigator |4 oth | |
| 700 | 1 | |a Betancourt, Ariana |e investigator |4 oth | |
| 700 | 1 | |a Bower, Georgie |e investigator |4 oth | |
| 700 | 1 | |a Cossetti, Chiara |e investigator |4 oth | |
| 700 | 1 | |a De Sa, Aloka |e investigator |4 oth | |
| 700 | 1 | |a Epping, Madeline |e investigator |4 oth | |
| 700 | 1 | |a Fawke, Stuart |e investigator |4 oth | |
| 700 | 1 | |a Gleadall, Nick |e investigator |4 oth | |
| 700 | 1 | |a Grenfell, Richard |e investigator |4 oth | |
| 700 | 1 | |a Hinch, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Huhn, Oisin |e investigator |4 oth | |
| 700 | 1 | |a Jackson, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Jarvis, Isobel |e investigator |4 oth | |
| 700 | 1 | |a Lewis, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Marsden, Joe |e investigator |4 oth | |
| 700 | 1 | |a Nice, Francesca |e investigator |4 oth | |
| 700 | 1 | |a Okecha, Georgina |e investigator |4 oth | |
| 700 | 1 | |a Omarjee, Ommar |e investigator |4 oth | |
| 700 | 1 | |a Perera, Marianne |e investigator |4 oth | |
| 700 | 1 | |a Richoz, Nathan |e investigator |4 oth | |
| 700 | 1 | |a Romashova, Veronika |e investigator |4 oth | |
| 700 | 1 | |a Yarkoni, Natalia Savinykh |e investigator |4 oth | |
| 700 | 1 | |a Sharma, Rahul |e investigator |4 oth | |
| 700 | 1 | |a Stefanucci, Luca |e investigator |4 oth | |
| 700 | 1 | |a Stephens, Jonathan |e investigator |4 oth | |
| 700 | 1 | |a Strezlecki, Mateusz |e investigator |4 oth | |
| 700 | 1 | |a Turner, Lori |e investigator |4 oth | |
| 700 | 1 | |a De Bie, Eckart M D D |e investigator |4 oth | |
| 700 | 1 | |a Bunclark, Katherine |e investigator |4 oth | |
| 700 | 1 | |a Josipovic, Masa |e investigator |4 oth | |
| 700 | 1 | |a Mackay, Michael |e investigator |4 oth | |
| 700 | 1 | |a Rossi, Sabrina |e investigator |4 oth | |
| 700 | 1 | |a Selvan, Mayurun |e investigator |4 oth | |
| 700 | 1 | |a Spencer, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Yong, Cissy |e investigator |4 oth | |
| 700 | 1 | |a Ansaripour, Ali |e investigator |4 oth | |
| 700 | 1 | |a Michael, Alice |e investigator |4 oth | |
| 700 | 1 | |a Mwaura, Lucy |e investigator |4 oth | |
| 700 | 1 | |a Patterson, Caroline |e investigator |4 oth | |
| 700 | 1 | |a Polwarth, Gary |e investigator |4 oth | |
| 700 | 1 | |a Polgarova, Petra |e investigator |4 oth | |
| 700 | 1 | |a di Stefano, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Fahey, Codie |e investigator |4 oth | |
| 700 | 1 | |a Michel, Rachel |e investigator |4 oth | |
| 700 | 1 | |a Bong, Sze-How |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Nature |d 1945 |g 592(2021), 7853 vom: 03. Apr., Seite 277-282 |w (DE-627)NLM000008257 |x 1476-4687 |7 nnns |
| 773 | 1 | 8 | |g volume:592 |g year:2021 |g number:7853 |g day:03 |g month:04 |g pages:277-282 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41586-021-03291-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 592 |j 2021 |e 7853 |b 03 |c 04 |h 277-282 | ||